Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Gut Bacteria Consumes Neurochemical Linked To Depression

XTALKS VITALS NEWS

Microbiome

This is the first time a bacterial species has been found which uses a neurotransmitter as an energy source.

Tweetables from this article:

Tweet: Gut bacteria has been found to consume GABA, a neurochemical found in the brain http://ctt.ec/btv19+Gut bacteria has been found to consume GABA, a neurochemical found in the brain.

Tweet: Low levels of GABA have been linked to depression and other mood disorders http://ctt.ec/s588n+Low levels of GABA have been linked to depression and other mood disorders.

Share this!

July 5, 2016 | by Sarah Massey, M.Sc.

A recently-discovered strain of gut bacteria has been found to consume GABA, a neurochemical found in the brain. The neurotransmitter has a calming effect on the brain, and the bacteria’s reliance on GABA could explain how the microbiome has an effect on mood.

The bacterial species found in the gut – called KLE1738 – was found to grow in culture only when supplemented with GABA molecules. “Nothing made it grow, except GABA,” said Philip Strandwitz, a postdoctoral research associate from Northeastern University in Boston. Strandwitz and his colleagues presented their findings at the annual meeting of the American Society for Microbiology, in June.

This is the first time a bacterial species has been found which uses a neurotransmitter as an energy source. As GABA calms down brain activity by inhibiting signals between nerve cells, the researchers were surprised to find that it’s necessary for some microbial life.

Low levels of GABA have been linked to symptoms of depression and other mood disorders, further suggesting that the microbiome could have an influence on our brain. Another species of bacteria, Lactobacillus rhamnosus, was previously found to change the activity of GABA in mouse brains.



When researchers in the same study removed the vagus nerve in the mice, they found that the ability of the Lactobacillus rhamnosus to influence the GABA activity was diminished. Since the vagus nerve links the gut to the brain, the researchers postulated that it likely plays a role in the way in which the gut bacteria influence the brain.

Strandwitz and his colleagues are now studying the microbiome to identify any other bacteria that might consume, or produce, GABA. By studying the effects these microbes have on the brain, he hopes to eventually identify new treatments for depression, anxiety and other mood disorders.

“Although research on microbial communities related to psychiatric disorders may never lead to a cure, it could have astonishing relevance to improving patients’ quality of life,” said Domenico Simone of George Washington University in Ashburn, Virginia.


Keywords: Microbiome, Neurotransmitter, Depression


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News


New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News


Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases


Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects


Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance


Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned


Copyright © 2016-2017 Honeycomb Worldwide Inc.